Twist Bioscience Company Insiders
| TWST Stock | USD 47.66 1.98 3.99% |
Twist Bioscience's insiders are aggressively selling. The analysis of the overall insider sentiment regarding Twist Bioscience Corp suggests that vertually all insiders are panicking. Twist Bioscience employs about 979 people. The company is managed by 19 executives with a total tenure of roughly 47 years, averaging almost 2.0 years of service per executive, having 51.53 employees per reported executive.
| Emily Leproust CEO President CEO, Director |
| Patrick Finn President Vice President of Sales and Marketing |
Insider Sentiment 0
Mostly Selling
Selling | Buying |
Latest Trades
| 2026-02-06 | Jan Johannessen | Disposed 2200 @ 47.91 | View | ||
| 2026-02-04 | Robert F Werner | Disposed 7000 @ 45.65 | View | ||
| 2026-02-03 | Robert F Werner | Disposed 175 @ 46.58 | View | ||
| 2026-01-13 | Adam Laponis | Disposed 3000 @ 40 | View | ||
| 2026-01-09 | Adam Laponis | Disposed 2738 @ 35.26 | View | ||
| 2025-12-22 | Dennis Cho | Disposed 324 @ 34.56 | View | ||
| 2025-11-03 | Robert F Werner | Disposed 160 @ 32.08 | View | ||
| 2025-10-30 | Robert F Werner | Disposed 1016 @ 31.44 | View |
Monitoring Twist Bioscience's insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Twist Bioscience Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in producer price index. Twist Bioscience's Workforce Through the Years
Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Twist Bioscience's future performance. Based on our forecasts, it is anticipated that Twist will maintain a workforce of slightly above 980 employees by March 2026.Twist Bioscience Management Team Effectiveness
The company has return on total asset (ROA) of (0.1349) % which means that it has lost $0.1349 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.1679) %, meaning that it created substantial loss on money invested by shareholders. Twist Bioscience's management efficiency ratios could be used to measure how well Twist Bioscience manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to gain to -0.13 in 2026. Return On Capital Employed is likely to drop to -0.23 in 2026. Non Current Liabilities Total is likely to gain to about 84.1 M in 2026, whereas Total Current Liabilities is likely to drop slightly above 54.2 M in 2026.Common Stock Shares Outstanding is likely to drop to about 44.8 M in 2026. Net Loss is likely to gain to about (186.3 M) in 2026Twist Bioscience Corp shows a total of 61.31 Million outstanding shares. The majority of Twist Bioscience Corp outstanding shares are owned by institutional holders. These institutional investors are usually referred to as non-private investors looking to take positions in Twist Bioscience to benefit from reduced commissions. Consequently, institutions are subject to a different set of regulations than regular investors in Twist Bioscience Corp. Please pay attention to any change in the institutional holdings of Twist Bioscience Corp as this could imply that something significant has changed or is about to change at the company. Also note that roughly six hundred thirteen invesors are currently shorting Twist Bioscience expressing very little confidence in its future performance.
Shares in Circulation | First Issued 2017-06-30 | Previous Quarter 60.4 M | Current Value 61.1 M | Avarage Shares Outstanding 44.7 M | Quarterly Volatility 15.1 M |
Twist Bioscience Workforce Comparison
Twist Bioscience Corp is rated third in number of employees category among its peers. The total workforce of Health Care industry is at this time estimated at about 13,390. Twist Bioscience holds roughly 979 in number of employees claiming about 7% of equities under Health Care industry.
The company has Profit Margin (PM) of (0.2) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.32) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.32. Twist Bioscience Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Twist Bioscience insiders, such as employees or executives, is commonly permitted as long as it does not rely on Twist Bioscience's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Twist Bioscience insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
| Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
|---|---|---|---|---|---|
| 2026-03-01 | 0.6154 | 8 | 13 | 38,944 | 56,060 |
| 2025-12-01 | 0.3077 | 12 | 39 | 660,716 | 184,910 |
| 2025-09-01 | 0.0385 | 1 | 26 | 14,353 | 30,325 |
| 2025-03-01 | 0.2143 | 6 | 28 | 26,832 | 41,673 |
| 2024-12-01 | 0.4865 | 18 | 37 | 520,155 | 122,970 |
| 2024-03-01 | 0.36 | 9 | 25 | 115,705 | 24,566 |
| 2023-12-01 | 0.4643 | 13 | 28 | 503,123 | 40,642 |
| 2023-09-01 | 0.2174 | 5 | 23 | 156,355 | 15,695 |
| 2023-06-01 | 0.1852 | 5 | 27 | 102,044 | 29,115 |
| 2023-03-01 | 0.1951 | 8 | 41 | 88,110 | 22,862 |
| 2022-12-01 | 0.4706 | 8 | 17 | 163,316 | 19,020 |
| 2022-09-01 | 0.0698 | 3 | 43 | 19,014 | 64,070 |
| 2022-06-01 | 0.2105 | 8 | 38 | 24,321 | 52,961 |
| 2022-03-01 | 0.4286 | 21 | 49 | 77,590 | 43,608 |
| 2021-12-01 | 0.3967 | 48 | 121 | 267,046 | 314,943 |
| 2021-09-01 | 0.265 | 31 | 117 | 125,314 | 418,366 |
| 2021-06-01 | 0.2727 | 30 | 110 | 83,065 | 600,326 |
| 2021-03-01 | 0.2692 | 42 | 156 | 151,144 | 810,511 |
| 2020-12-01 | 0.1888 | 27 | 143 | 188,811 | 593,487 |
| 2020-09-01 | 0.375 | 36 | 96 | 536,786 | 3,029,295 |
| 2020-06-01 | 0.1163 | 5 | 43 | 26,258 | 256,134 |
| 2020-03-01 | 0.5349 | 23 | 43 | 140,502 | 296,472 |
| 2019-12-01 | 0.5161 | 32 | 62 | 609,579 | 390,162 |
| 2019-09-01 | 0.2436 | 19 | 78 | 109,760 | 233,872 |
| 2019-06-01 | 4.0 | 4 | 1 | 41,067 | 0.00 |
| 2018-12-01 | 0.7647 | 39 | 51 | 12,969,273 | 15,821,221 |
Twist Bioscience Notable Stakeholders
A Twist Bioscience stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Twist Bioscience often face trade-offs trying to please all of them. Twist Bioscience's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Twist Bioscience's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Emily Leproust | President CEO, Director | Profile | |
| Patrick Finn | Vice President of Sales and Marketing | Profile | |
| Paula Green | Vice President of Human Resources | Profile | |
| Dennis Cho | General VP | Profile | |
| Robert Werner | VP Officer | Profile | |
| William Banyai | GM Development | Profile | |
| Mark Buck | Senior Operations | Profile | |
| Jimmy Jin | Senior Marketing | Profile | |
| Dennis JD | Chief Secretary | Profile | |
| Kevin Yankton | VP Officer | Profile | |
| Chet Gandhi | Chief Officer | Profile | |
| Michael Fero | Chief Officer | Profile | |
| Nicole Moreno | Senior Support | Profile | |
| Siyuan Chen | Chief Officer | Profile | |
| Aaron Sato | Chief Officer | Profile | |
| James Thorburn | Chief Officer | Profile | |
| Erin Smith | Sr Policy | Profile | |
| Adam Laponis | Chief Officer | Profile | |
| Angela Bitting | Chief Affairs | Profile |
About Twist Bioscience Management Performance
The success or failure of an entity such as Twist Bioscience Corp often depends on how effective the management is. Twist Bioscience management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Twist management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Twist management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.14) | (0.13) | |
| Return On Capital Employed | (0.22) | (0.23) | |
| Return On Assets | (0.12) | (0.11) | |
| Return On Equity | (0.19) | (0.20) |
Please note, the imprecision that can be found in Twist Bioscience's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Twist Bioscience Corp. Check Twist Bioscience's Beneish M Score to see the likelihood of Twist Bioscience's management manipulating its earnings.
Twist Bioscience Workforce Analysis
Traditionally, organizations such as Twist Bioscience use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Twist Bioscience within its industry.Twist Bioscience Manpower Efficiency
Return on Twist Bioscience Manpower
| Revenue Per Employee | 384.6K | |
| Revenue Per Executive | 19.8M | |
| Net Loss Per Employee | 79.3K | |
| Net Loss Per Executive | 4.1M | |
| Working Capital Per Employee | 246.7K | |
| Working Capital Per Executive | 12.7M |
Additional Tools for Twist Stock Analysis
When running Twist Bioscience's price analysis, check to measure Twist Bioscience's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Twist Bioscience is operating at the current time. Most of Twist Bioscience's value examination focuses on studying past and present price action to predict the probability of Twist Bioscience's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Twist Bioscience's price. Additionally, you may evaluate how the addition of Twist Bioscience to your portfolios can decrease your overall portfolio volatility.